For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
Dexcom Inc (NASDAQ: DXCM) closed the day trading at $58.22 down -14.63% from the previous closing price of $68.2. In other words, the price has decreased by -$14.63 from its previous closing price. On the day, 26.55 million shares were traded. DXCM stock price reached its highest trading level at $60.36 during the session, while it also had its lowest trading level at $56.445.
Ratios:
For a better understanding of DXCM, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.84 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 21.38. For the most recent quarter (mrq), Quick Ratio is recorded 1.38 and its Current Ratio is at 1.56. In the meantime, Its Debt-to-Equity ratio is 0.94 whereas as Long-Term Debt/Eq ratio is at 0.49.
On August 21, 2025, Argus started tracking the stock assigning a Buy rating and target price of $100.Argus initiated its Buy rating on August 21, 2025, with a $100 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 05 ’25 when Malady Kyle sold 667 shares for $80.86 per share. The transaction valued at 53,934 led to the insider holds 22,667 shares of the business.
Stern Sadie sold 1,466 shares of DXCM for $117,280 on Sep 04 ’25. The EVP, Chief HR Officer now owns 105,223 shares after completing the transaction at $80.00 per share. On Sep 05 ’25, another insider, Malady Kyle, who serves as the Director of the company, bought 667 shares for $80.86 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DXCM now has a Market Capitalization of 22706747392 and an Enterprise Value of 21960247296. As of this moment, Dexcom’s Price-to-Earnings (P/E) ratio for their current fiscal year is 32.40, and their Forward P/E ratio for the next fiscal year is 23.18. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.45. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.03 while its Price-to-Book (P/B) ratio in mrq is 8.33. Its current Enterprise Value per Revenue stands at 4.863 whereas that against EBITDA is 21.485.
Stock Price History:
The Beta on a monthly basis for DXCM is 1.42, which has changed by -0.16470587 over the last 52 weeks, in comparison to a change of 0.19736934 over the same period for the S&P500. Over the past 52 weeks, DXCM has reached a high of $93.25, while it has fallen to a 52-week low of $57.52. The 50-Day Moving Average of the stock is -18.09%, while the 200-Day Moving Average is calculated to be -25.61%.
Shares Statistics:
Over the past 3-months, DXCM traded about 5.10M shares per day on average, while over the past 10 days, DXCM traded about 6921310 shares per day. A total of 390.00M shares are outstanding, with a floating share count of 384.61M. Insiders hold about 1.38% of the company’s shares, while institutions hold 93.63% stake in the company. Shares short for DXCM as of 1760486400 were 11617322 with a Short Ratio of 2.28, compared to 1757894400 on 13142220. Therefore, it implies a Short% of Shares Outstanding of 11617322 and a Short% of Float of 3.8.
Earnings Estimates
. The current rating of Dexcom Inc (DXCM) reflects the combined expertise of 23.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.48, with high estimates of $0.55 and low estimates of $0.4.
Analysts are recommending an EPS of between $2.17 and $1.96 for the fiscal current year, implying an average EPS of $2.07. EPS for the following year is $2.5, with 25.0 analysts recommending between $2.76 and $2.29.
Revenue Estimates
23 analysts predict $1.24B in revenue for . The current quarter. It ranges from a high estimate of $1.27B to a low estimate of $1.23B. As of . The current estimate, Dexcom Inc’s year-ago sales were $1.11BFor the next quarter, 23 analysts are estimating revenue of $1.18B. There is a high estimate of $1.26B for the next quarter, whereas the lowest estimate is $1.13B.
A total of 25 analysts have provided revenue estimates for DXCM’s current fiscal year. The highest revenue estimate was $4.65B, while the lowest revenue estimate was $4.61B, resulting in an average revenue estimate of $4.64B. In the same quarter a year ago, actual revenue was $4.03BBased on 26 analysts’ estimates, the company’s revenue will be $5.24B in the next fiscal year. The high estimate is $5.38B and the low estimate is $5.14B.
